血清CXCL12浓度对重型颅脑损伤患者预后的预测价值分析  

作　　者：蔡庸 庄耀坤 董晓巧 杜权[2] 沈良军[3] 裘申忠 郑永科[2] 俞文华[2] 

机构地区：[1]浙江中医药大学第四临床医学院,310053 [2]杭州市第一人民医院,310006 [3]浙江省嵊州市人民医院,312400 [4]浙江省杭州市富阳区第一人民医院,311400

出　　处：《浙江临床医学》2021年第5期666-668,共3页Zhejiang Clinical Medical Journal

基　　金：杭州市科技计划项目(20180533B43)。

摘　　要：目的探讨血清CXCL12浓度对重型颅脑损伤(sTBI)患者预后的预测价值.方法选取sTBI患者106例为外伤组和健康自愿者106例为对照组,采用ELISA法测定血清CXCL12和C-反应蛋白浓度,采用格拉斯哥昏迷评分评估伤情严重度,分析sTBI患者血清CXCL12浓度的变化及其与严重度、炎症反应和住院期间主要不良事件的相关性.结果外伤组血清CXCL12浓度比对照组升高(P<0.01),外伤组血清CXCL12浓度与入院时格拉斯哥昏迷评分和血清C-反应蛋白浓度存在相关性(均P<0.01),是住院期间主要不良事件发生的独立预测因素(均P<0.05),对住院期间主要不良事件发生具有较高的辨别能力(均P<0.01).结论CXCL12可能参与创伤后炎症性脑损伤,其升高水平与创伤性脑损伤严重度及临床预后密切相关.Objective To study the prognostic value of serum CXCL12 concentration in patients with severe craniocerebral injury.Methods A total of 106 severe traumatic brain injury patients and 106 healthy volunteers were selected to constitute trauma group and control group respectively,ELISA was done to measure serum CXCL12 and C-reactive protein concentrations,Glasgow coma scale scores were recorded to estimate trauma severity,and statistical analyses were done to discern change of serum CXCL 12 concentrations in patients with severe traumatic brain injury as well as its correlation with severity,infAammatory reaction and in-hospital major adverse events.Results Serum CXCL12 concentrations in trauma group were substantially higher than those in control group(P<0.01),serum CXCL12 concentrations in trauma group were highly correlated with adnmission Glasgow coma scale scores and serum C-reactive protein levels(both P<0.01),serum CXCL12 was identified as an independent predictor for the occurrence of in--hospial major adverse events(all P<0.05),it also exhibited rather high discriminatory ability for the occurrence of in-hospital major adverse events(all P<0.01).Conclusion CXCL12 may be implicated in posttraumatic inflammatory brain injury and an elevation in its serum levels is in intimate correlation with severity of traumatic brain injury and clinical outcomes.

关 键 词：CXCL12 颅脑损伤 严重度 预后 炎症反应 

分 类 号：R73[医药卫生—肿瘤]